<DOC>
	<DOCNO>NCT00004409</DOCNO>
	<brief_summary>OBJECTIVES : Evaluate safety efficacy collagenase improve flexion deformity , range motion , grip strength patient residual Dupuytren 's disease .</brief_summary>
	<brief_title>Phase II Randomized Study Collagenase Patients With Residual Type Dupuytren 's Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , investigator-blinded , placebo-controlled study . Patients receive single dose either collagenase placebo target finger day 0 . Patients respond 1 month follow visit may receive injection open label collagenase , IgE antibody level great 15 ng/mL . Following treatment , patient use nighttime extension splint 4 month perform finger flexion/extension exercise . Patients follow 1 , 7 , 14 day , 1 , 2 , 3 , 6 , 9 , 12 month , joint treat . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Contracture</mesh_term>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis residual Dupuytren 's disease fix flexion deformity finger least 2030 degree cause palpable cord Positive table top test ( inability simultaneously place affect finger palm flat table top ) Prior/Concurrent Therapy Surgery : At least 30 day since surgery Dupuytren 's disease Other : At least 30 day since prior investigational drug Patient Characteristics Hematopoietic : No history hematologic disease Hepatic : No history hepatic disease Renal : No history renal disease Cardiovascular : No congestive heart failure within 6 month No angina within 6 month No myocardial infarction within 6 month Pulmonary : No history respiratory disease Other : HIV negative Not immunocompromised No history significant illness , e.g. , endocrine neurologic disease No history illicit drug abuse alcoholism within 1 year No psychosis At least 2 week since infectious illness No chronic debilitate disease No IgE antibodies collagenase great 15 ng/mL No known allergy collagenase inactive ingredient injection Not pregnant nursing Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>Dupuytren 's disease</keyword>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>rare disease</keyword>
</DOC>